FDA Priority Reviews and Cell Therapy Acquisitions Signal Biotech Sector Acceleration
Biotechnology companies are advancing through key regulatory milestones as FDA accelerated pathways create commercial momentum. Daiichi Sankyo's antibody drug conjugate received Priority Review for small cell lung cancer, while Mesoblast acquired CAR platform technology to enhance cell therapy products. Clinical-stage firms like Spyre Therapeutics are pursuing equity offerings to fund pipeline development.
Salvado•